Abbott’s Interferon-free Hep C Combo With Ribavirin Has High Cure Rates
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott revealed more data from its Phase II Aviator program Nov. 10 during a press conference at the American Association for the Study of Liver Disease meeting showing high cure rates in some difficult patient populations and a 100% cure rate for the easier to treat genotype 1 subgroup.
You may also be interested in...
As AbbVie Prepares To Launch, Some Wind Gets Knocked Out Of Its Sails
Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.